Search

Your search keyword '"Scher, Jose U."' showing total 310 results
Start Over Author "Scher, Jose U." Publication Type Academic Journals
310 results on '"Scher, Jose U."'

1. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study

Author

Ogdie, Alexis, Merola, Joseph F., Mease, Philip J., Ritchlin, Christopher T., Scher, Jose U., Lafferty, Kimberly Parnell, Chan, Daphne, Chakravarty, Soumya D., Langholff, Wayne, Wang, Yanli, Choi, Olivia, Krol, Yevgeniy, and Gottlieb, Alice B.

Published
2024
Full Text
View/download PDF

4. New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine

Author

Yan, Di, Gudjonsson, Johann E, Le, Stephanie, Maverakis, Emanual, Plazyo, Olesya, Ritchlin, Christopher, Scher, Jose U, Singh, Roopesh, Ward, Nicole L, Bell, Stacie, and Liao, Wilson

Subjects
Biomedical and Clinical Sciences, Immunology, Autoimmune Disease, Clinical Research, Psoriasis, Rare Diseases, 2.1 Biological and endogenous factors, Aetiology, Inflammatory and immune system, Good Health and Well Being, Animals, Gene-Environment Interaction, Humans, Inflammation, Precision Medicine, Skin, Clinical Sciences, Oncology and Carcinogenesis, Dermatology & Venereal Diseases, Clinical sciences
Abstract

Psoriasis is a chronic inflammatory condition characterized by systemic immune dysregulation. Over the past several years, advances in genetics, microbiology, immunology, and mouse models have revealed the complex interplay between the heritable and microenvironmental factors that drive the development of psoriatic inflammation. In the first of this two-part review series, the authors will discuss the newest insights into the pathogenesis of psoriatic disease and highlight how the evolution of these scientific fields has paved the way for a more personalized approach to psoriatic disease treatment.

Published
2021

5. Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: A 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registry

Author

Jin, Joy Q., Cronin, Angel, Roberts-Toler, Carla, Yeroushalmi, Samuel, Hadeler, Edward, Spencer, Riley K., Elhage, Kareem G., Gondo, George, Wallace, Elizabeth B., Reddy, Soumya M., Han, George, Kaffenberger, Jessica, Davis, Mitchell S., Hakimi, Marwa, Scher, Jose U., Armstrong, April W., Bhutani, Tina, McLean, Robert R., and Liao, Wilson

Published
2023
Full Text
View/download PDF

6. Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation

Author

Nayak, Renuka R, Alexander, Margaret, Deshpande, Ishani, Stapleton-Gray, Kye, Rimal, Bipin, Patterson, Andrew D, Ubeda, Carles, Scher, Jose U, and Turnbaugh, Peter J

Subjects
Microbiology, Biological Sciences, Biomedical and Clinical Sciences, Arthritis, Autoimmune Disease, Women's Health, Microbiome, Rheumatoid Arthritis, Clinical Research, Infection, Oral and gastrointestinal, Inflammatory and immune system, Good Health and Well Being, Animals, Arthritis, Rheumatoid, Autoimmune Diseases, Bacteria, Female, Gastrointestinal Microbiome, Gastrointestinal Tract, Humans, Metabolomics, Methotrexate, Mice, Mice, Inbred C57BL, Phylogeny, Purines, Pyrimidines, RNA, Ribosomal, 16S, Tetrahydrofolate Dehydrogenase, Transcriptome, DMARD, autoimmune disease, human gut microbiome, immune activation, metabolomics, methotrexate, microbiota, off-target effects, purine and pyrimidine biosynthesis, rheumatoid arthritis, Medical Microbiology, Immunology, Biochemistry and cell biology, Medical microbiology
Abstract

Immunomodulatory drugs can inhibit bacterial growth, yet their mechanism of action, spectrum, and clinical relevance remain unknown. Methotrexate (MTX), a first-line rheumatoid arthritis (RA) treatment, inhibits mammalian dihydrofolate reductase (DHFR), but whether it directly impacts gut bacteria is unclear. We show that MTX broadly alters the human gut microbiota. Drug sensitivity varied across strains, but the mechanism of action against DHFR appears conserved between mammalian and bacterial cells. RA patient microbiotas were sensitive to MTX, and changes in gut bacterial taxa and gene family abundance were distinct between responders and non-responders. Transplantation of post-treatment samples into germ-free mice given an inflammatory trigger led to reduced immune activation relative to pre-treatment controls, enabling identification of MTX-modulated bacterial taxa associated with intestinal and splenic immune cells. Thus, conservation in cellular pathways across domains of life can result in broad off-target drug effects on the human gut microbiota with consequences for immune function.

Published
2021

7. Auto-deconvolution and molecular networking of gas chromatography-mass spectrometry data.

Author

Aksenov, Alexander A, Laponogov, Ivan, Zhang, Zheng, Doran, Sophie LF, Belluomo, Ilaria, Veselkov, Dennis, Bittremieux, Wout, Nothias, Louis Felix, Nothias-Esposito, Mélissa, Maloney, Katherine N, Misra, Biswapriya B, Melnik, Alexey V, Smirnov, Aleksandr, Du, Xiuxia, Jones, Kenneth L, Dorrestein, Kathleen, Panitchpakdi, Morgan, Ernst, Madeleine, van der Hooft, Justin JJ, Gonzalez, Mabel, Carazzone, Chiara, Amézquita, Adolfo, Callewaert, Chris, Morton, James T, Quinn, Robert A, Bouslimani, Amina, Orio, Andrea Albarracín, Petras, Daniel, Smania, Andrea M, Couvillion, Sneha P, Burnet, Meagan C, Nicora, Carrie D, Zink, Erika, Metz, Thomas O, Artaev, Viatcheslav, Humston-Fulmer, Elizabeth, Gregor, Rachel, Meijler, Michael M, Mizrahi, Itzhak, Eyal, Stav, Anderson, Brooke, Dutton, Rachel, Lugan, Raphaël, Boulch, Pauline Le, Guitton, Yann, Prevost, Stephanie, Poirier, Audrey, Dervilly, Gaud, Le Bizec, Bruno, Fait, Aaron, Persi, Noga Sikron, Song, Chao, Gashu, Kelem, Coras, Roxana, Guma, Monica, Manasson, Julia, Scher, Jose U, Barupal, Dinesh Kumar, Alseekh, Saleh, Fernie, Alisdair R, Mirnezami, Reza, Vasiliou, Vasilis, Schmid, Robin, Borisov, Roman S, Kulikova, Larisa N, Knight, Rob, Wang, Mingxun, Hanna, George B, Dorrestein, Pieter C, and Veselkov, Kirill

Subjects
Animals, Anura, Humans, Algorithms, Gas Chromatography-Mass Spectrometry, Metabolomics
Abstract

We engineered a machine learning approach, MSHub, to enable auto-deconvolution of gas chromatography-mass spectrometry (GC-MS) data. We then designed workflows to enable the community to store, process, share, annotate, compare and perform molecular networking of GC-MS data within the Global Natural Product Social (GNPS) Molecular Networking analysis platform. MSHub/GNPS performs auto-deconvolution of compound fragmentation patterns via unsupervised non-negative matrix factorization and quantifies the reproducibility of fragmentation patterns across samples.

Published
2021

9. Interleukin‐17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin‐25–Driven Intestinal Inflammation

Author

Manasson, Julia, Wallach, David S, Guggino, Giuliana, Stapylton, Matthew, Badri, Michelle H, Solomon, Gary, Reddy, Soumya M, Coras, Roxana, Aksenov, Alexander A, Jones, Drew R, Girija, Parvathy V, Neimann, Andrea L, Heguy, Adriana, Segal, Leopoldo N, Dorrestein, Pieter C, Bonneau, Richard, Guma, Monica, Ciccia, Francesco, Ubeda, Carles, Clemente, Jose C, and Scher, Jose U

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Digestive Diseases, Autoimmune Disease, Clinical Research, 2.1 Biological and endogenous factors, Aetiology, Inflammatory and immune system, Antibodies, Monoclonal, Humanized, Arthritis, Psoriatic, Female, Gastrointestinal Microbiome, Humans, Inflammation, Interleukin-17, Intestinal Mucosa, Intestines, Male, Middle Aged, Spondylarthritis, Tumor Necrosis Factor Inhibitors, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectiveTo characterize the ecological effects of biologic therapies on the gut bacterial and fungal microbiome in psoriatic arthritis (PsA)/spondyloarthritis (SpA) patients.MethodsFecal samples from PsA/SpA patients pre- and posttreatment with tumor necrosis factor inhibitors (TNFi; n = 15) or an anti-interleukin-17A monoclonal antibody inhibitor (IL-17i; n = 14) underwent sequencing (16S ribosomal RNA, internal transcribed spacer and shotgun metagenomics) and computational microbiome analysis. Fecal levels of fatty acid metabolites and cytokines/proteins implicated in PsA/SpA pathogenesis or intestinal inflammation were correlated with sequence data. Additionally, ileal biopsies obtained from SpA patients who developed clinically overt Crohn's disease (CD) after treatment with IL-17i (n = 5) were analyzed for expression of IL-23/Th17-related cytokines, IL-25/IL-17E-producing cells, and type 2 innate lymphoid cells (ILC2s).ResultsThere were significant shifts in abundance of specific taxa after treatment with IL-17i compared to TNFi, particularly Clostridiales (P = 0.016) and Candida albicans (P = 0.041). These subclinical alterations correlated with changes in bacterial community co-occurrence, metabolic pathways, IL-23/Th17-related cytokines, and various fatty acids. Ileal biopsies showed that clinically overt CD was associated with expansion of IL-25/IL-17E-producing tuft cells and ILC2s (P < 0.05), compared to pre-IL-17i treatment levels.ConclusionIn a subgroup of SpA patients, the initiation of IL-17A blockade correlated with features of subclinical gut inflammation and intestinal dysbiosis of certain bacterial and fungal taxa, most notably C albicans. Further, IL-17i-related CD was associated with overexpression of IL-25/IL-17E-producing tuft cells and ILC2s. These results may help to explain the potential link between inhibition of a specific IL-17 pathway and the (sub)clinical gut inflammation observed in SpA.

Published
2020

11. Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort

Author

Adhikari, Samrachana, Axelrad, Jordan, Azar, Natalie, Blank, Rebecca, Brancato, Lenore, Brodetskiy, Konstantin, Cao, Lily, Carlucci, Philip M., Carsons, Steven, Chang, Miao, Chang, Shannon, Chen, Alan, Colin, Michael, Fried, Lauren, Garner, Bruce, Goldberg, Avram, Golden, Brian, Golpanian, Michael, Haj-Ali, Mayce, Hoey, Jessica, Homsi, Yamen, Hong, Simon, Hudesman, David, Hussain, Nazia, Jaros, Brian, Katz, Susan, Kolla, Avani, Lee, Euna, Lee, Sicy, Lesser, Robert, Lipschitz, Robin, Lydon, Eileen, Malik, Fardina, Mangalick, Keshav, Mehta, Kavini, Modi, Anang, Neimann, Andrea, Novack, Joshua, Nusbaum, Julie, Peterson, Connor, Piatti, Andres, Plotz, Benjamin, Porges, Andrew, Quintana, Lindsey, Rackoff, Paula, Ramirez, Deborah, Rangel, Lauren, Reddy, Soumya, Robins, Kimberly, Rosenthal, Pamela, Samuels, Jonathan, Sandigursky, Sabina, Sekar, Vaish, Shankar, Shruti, Shen, Harry, Smiles, Stephen, Smuda, Craig, Solitar, Bruce, Solomon, Gary, Stein, Jennifer, Steuer, Alexa, Sullivan, Janine, Svigos, Katerina, Troxel, Andrea, Viennas, Stelios, Wong, Lauren, Yan, Di, Yin, Kaitlyn (Lu), Young, Trevor, Zagon, Gary, Saxena, Amit, Guttmann, Allison, Masson, Mala, Kim, Mimi Y, Haberman, Rebecca H, Castillo, Rochelle, Scher, Jose U, Deonaraine, Kristina K, Engel, Alexis J, Belmont, H Michael, Blazer, Ashira D, Buyon, Jill P, Fernandez-Ruiz, Ruth, and Izmirly, Peter M

Published
2021
Full Text
View/download PDF

12. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments

Author

Gelfand, Joel M., Armstrong, April W., Bell, Stacie, Anesi, George L., Blauvelt, Andrew, Calabrese, Cassandra, Dommasch, Erica D., Feldman, Steven R., Gladman, Dafna, Kircik, Leon, Lebwohl, Mark, Lo Re, Vincent, III, Martin, George, Merola, Joseph F., Scher, Jose U., Schwartzman, Sergio, Treat, James R., Van Voorhees, Abby S., Ellebrecht, Christoph T., Fenner, Justine, Ocon, Anthony, Syed, Maha N., Weinstein, Erica J., Gondo, George, Heydon, Sue, Koons, Samantha, and Ritchlin, Christopher T.

Published
2021
Full Text
View/download PDF

16. National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

Author

Gelfand, Joel M., Armstrong, April W., Bell, Stacie, Anesi, George L., Blauvelt, Andrew, Calabrese, Cassandra, Dommasch, Erica D., Feldman, Steve R., Gladman, Dafna, Kircik, Leon, Lebwohl, Mark, Lo Re, Vincent, III, Martin, George, Merola, Joseph F., Scher, Jose U., Schwartzman, Sergio, Treat, James R., Van Voorhees, Abby S., Ellebrecht, Christoph T., Fenner, Justine, Ocon, Anthony, Syed, Maha N., Weinstein, Erica J., Smith, Jessica, Gondo, George, Heydon, Sue, Koons, Samantha, and Ritchlin, Christopher T.

Published
2020
Full Text
View/download PDF

18. Mitigation of Osteoclast‐Mediated Arthritic Bone Remodeling By Short Chain Fatty Acids.

Author

Yang, Katharine Lu, Mullins, Briana J., Lejeune, Alannah, Ivanova, Ellie, Shin, Jong, Bajwa, Sofia, Possemato, Richard, Cadwell, Ken, Scher, Jose U., and Koralov, Sergei B.

Subjects
OSTEOPOROSIS prevention, FLOW cytometry, SHORT-chain fatty acids, DATA analysis, POLYMERASE chain reaction, COMPUTED tomography, ENZYME-linked immunosorbent assay, MANN Whitney U Test, DESCRIPTIVE statistics, MICE, GAS chromatography, RNA, OSTEOCLASTS, ARTHRITIS, ANIMAL experimentation, MASS spectrometry, STATISTICS, HEMATOPOIETIC stem cells, STEM cells, DATA analysis software, BONE remodeling, PHENOTYPES, GENOTYPES, SEQUENCE analysis, NONPARAMETRIC statistics
Abstract

Objective: The objective for this study was to evaluate the effects of short chain fatty acids (SCFAs) on arthritic bone remodeling. Methods: We treated a recently described preclinical murine model of psoriatic arthritis (PsA), R26STAT3Cstopfl/fl CD4Cre mice, with SCFA‐supplemented water. We also performed in vitro osteoclast differentiation assays in the presence of serum‐level SCFAs to evaluate the direct impact of these microbial metabolites on maturation and function of osteoclasts. We further characterized the molecular mechanism of SCFAs by transcriptional analysis. Results: The osteoporosis condition in R26STAT3Cstopfl/fl CD4Cre animals is attributed primarily to robust osteoclast differentiation driven by an expansion of osteoclast progenitor cells (OCPs), accompanied by impaired osteoblast development. We show that SCFA supplementation can rescue the osteoporosis phenotype in this model of PsA. Our in vitro experiments revealed an inhibitory effect of the SCFAs on osteoclast differentiation, even at very low serum concentrations. This suppression of osteoclast differentiation enabled SCFAs to impede osteoporosis development in R26STAT3Cstopfl/fl CD4Cre mice. Further interrogation revealed that bone marrow–derived OCPs from diseased mice expressed a higher level of SCFA receptors than those of control mice and that the progenitor cells in the bone marrow of SCFA‐treated mice presented a modified transcriptomic landscape, suggesting a direct impact of SCFAs on bone marrow progenitors in the context of osteoporosis. Conclusion: We demonstrated how gut microbiota‐derived SCFAs can regulate distal pathology (ie, osteoporosis) and identified a potential therapeutic option for restoring bone density in rheumatic disease, further highlighting the critical role of the gut–bone axis in these disorders. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Psoriatic arthritis

Author

FitzGerald, Oliver, Ogdie, Alexis, Chandran, Vinod, Coates, Laura C., Kavanaugh, Arthur, Tillett, William, Leung, Ying Ying, deWit, Maarten, Scher, Jose U., and Mease, Philip J.

Published
2021
Full Text
View/download PDF

21. KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease

Author

Billi, Allison C., Ludwig, Jessica E., Fritz, Yi, Rozic, Richard, Swindell, William R., Tsoi, Lam C., Gruzska, Dennis, Abdollahi-Roodsaz, Shahla, Xing, Xianying, Diaconu, Doina, Uppala, Ranjitha, Camhi, Maya I., Klenotic, Philip A., Sarkar, Mrinal K., Husni, M. Elaine, Scher, Jose U., McDonald, Christine, Kahlenberg, J. Michelle, Midura, Ronald J., Gudjonsson, Johann E., and Ward, Nicole L.

Subjects
Kallikrein, Inflammation, Dermatologic agents, Vorapaxar, Psoriasis, Skin, Drug approval, Arthritis, Dermatitis, Health care industry
Abstract

Kallikrein-related peptidase 6 (KLK6) is a secreted serine protease hypothesized to promote inflammation via cleavage of protease-activated receptor 1 (PAR1) and PAR2. KLK6 levels are elevated in multiple inflammatory and autoimmune conditions, but no definitive role in pathogenesis has been established. Here, we show that skin-targeted overexpression of KLK6 causes generalized, severe psoriasiform dermatitis with spontaneous development of debilitating psoriatic arthritis-like joint disease. The psoriatic skin and joint phenotypes are reversed by normalization of skin KLK6 levels and attenuated following genetic elimination of PAR1 but not PAR2. Conservation of this regulatory pathway was confirmed in human psoriasis using vorapaxar, an FDA-approved PAR1 antagonist, on explanted lesional skin from patients with psoriasis. Beyond defining a critical role for KLK6/PAR1 signaling in promoting psoriasis, our results demonstrate that KLK6/PAR1-mediated inflammation in the skin alone is sufficient to drive inflammatory joint disease. Further, we identify PAR1 as a promising cytokine-independent target in therapy of psoriasis and psoriatic arthritis., Introduction Psoriasis is a chronic, incurable systemic inflammatory disease with complex and incompletely understood pathogenesis. Two percent to 3% of the population worldwide suffers from psoriasis, and affected individuals show [...]

Published
2020
Full Text
View/download PDF

34. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism

Author

Zanin-Zhorov, Alexandra, Weiss, Jonathan M., Nyuydzefe, Melanie S., Chen, Wei, Scher, Jose U., Mo, Rigen, Depoil, David, Rao, Nishta, Liu, Ben, Wei, Jianlu, Lucas, Sarah, Koslow, Matthew, Roche, Maria, Schueller, Olivier, Weiss, Sara, Poyurovsky, Masha V., Tonra, James, Hippen, Keli L, Dustin, Michael L., Blazar, Bruce R., Liu, Chuan-ju, Waksal, Samuel D., and Dinarello, Charles A.

Published
2014

41. Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City

Author

Saxena, Amit, Engel, Alexis J, Banbury, Brittany, Hasan, Ghadeer, Fraser, Nicola, Zaminski, Devyn, Masson, Mala, Haberman, Rebecca H, Scher, Jose U, Ho, Gary, Law, Jammie, Rackoff, Paula, Tseng, Chung-E, Belmont, H Michael, Clancy, Robert M, Buyon, Jill P, and Izmirly, Peter M

Published
2022
Full Text
View/download PDF

42. Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease

Author

Haberman, Rebecca H, Um, Seungha, Axelrad, Jordan E, Blank, Rebecca B, Uddin, Zakwan, Catron, Sydney, Neimann, Andrea L, Mulligan, Mark J, Herat, Ramin Sedaghat, Hong, Simon J, Chang, Shannon, Myrtaj, Arnold, Ghiasian, Ghoncheh, Izmirly, Peter M, Saxena, Amit, Solomon, Gary, Azar, Natalie, Samuels, Jonathan, Golden, Brian D, Rackoff, Paula, Adhikari, Samrachana, Hudesman, David P, and Scher, Jose U

Published
2022
Full Text
View/download PDF

46. Low incidence and transient elevation of autoantibodies post mRNA COVID-19 vaccination in inflammatory arthritis.

Author

Blank, Rebecca B, Haberman, Rebecca H, Qian, Kun, Samanovic, Marie, Castillo, Rochelle, Hernandez, Anthony Jimenez, Girija, Parvathy Vasudevapillai, Catron, Sydney, Uddin, Zakwan, Rackoff, Paula, Solomon, Gary, Azar, Natalie, Rosenthal, Pamela, Izmirly, Peter, Samuels, Jonathan, Golden, Brian, Reddy, Soumya, Mulligan, Mark J, Hu, Jiyuan, and Scher, Jose U

Subjects
AUTOANTIBODIES, IMMUNIZATION, COVID-19 vaccines, SERUM, SEROCONVERSION, DISEASE incidence, COMPARATIVE studies, TREATMENT effectiveness, MESSENGER RNA, RHEUMATOID arthritis, ENZYME-linked immunosorbent assay, DESCRIPTIVE statistics, LONGITUDINAL method, PHARMACODYNAMICS
Abstract

Objectives Autoantibody seroconversion has been extensively studied in the context of COVID-19 infection but data regarding post-vaccination autoantibody production is lacking. Here we aimed to determine the incidence of common autoantibody formation following mRNA COVID-19 vaccines in patients with inflammatory arthritis (IA) and in healthy controls. Methods Autoantibody seroconversion was measured by serum ELISA in a longitudinal cohort of IA participants and healthy controls before and after COVID-19 mRNA-based immunization. Results Overall, there was a significantly lower incidence of ANA seroconversion in participants who did not contract COVID-19 prior to vaccination compared with those who been previously infected (7.4% vs 24.1%, P  = 0.014). Incidence of de novo anti-CCP seroconversion in all participants was low at 4.9%. Autoantibody levels were typically of low titre, transient, and not associated with increase in IA flares. Conclusions In both health and inflammatory arthritis, the risk of autoantibody seroconversion is lower following mRNA-based immunization than following natural SARS-CoV-2 infection. Importantly, seroconversion does not correlate with self-reported IA disease flare risk, further supporting the encouragement of mRNA-based COVID-19 immunization in the IA population. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results